India, May 19 -- British drug maker GSK plc (GSK.L, GSK) announced Monday the approval of Blenrep combinations by Japan's Ministry of Health, Labour and Welfare or MHLW for the treatment of adults with relapsed or refractory multiple myeloma.
The approval follows superior efficacy shown in two head-to-head phase III trials, including overall survival in DREAMM-7. The company noted that it is the second major approval for Blenrep combinations, with more expected in 2025. The first authorisation in the world was by the UK Medicines and Healthcare products Regulatory Agency (MHRA) last month.
Multiple myeloma is the third most common blood cancer globally and is generally considered treatable but not curable.
The Japan's decision was based ...